Predicting retroperitoneal histology in postchemotherapy testicular germ cell cancer: a model update and multicentre validation with more than 1000 patients.

[1]  B. Carver,et al.  Germ Cell Tumors of the Testis , 2005, Annals of Surgical Oncology.

[2]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[3]  Rodney X. Sturdivant,et al.  Applied Logistic Regression: Hosmer/Applied Logistic Regression , 2005 .

[4]  W. Siegert,et al.  European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  R. Fimmers,et al.  Prediction of necrosis after chemotherapy of advanced germ cell tumors: results of a prospective multicenter trial of the German Testicular Cancer Study Group. , 2004, The Journal of urology.

[6]  R. Bihrle,et al.  Secondary surgery in germ cell tumors—when and how extensively should it be performed? , 2004, World Journal of Urology.

[7]  Laurence B McCullough,et al.  A Typology of Shared Decision Making, Informed Consent, and Simple Consent , 2004, Annals of Internal Medicine.

[8]  J. Habbema,et al.  External validity of a prediction rule for residual mass histology in testicular cancer: an evaluation for good prognosis patients , 2003, British Journal of Cancer.

[9]  D. Dearnaley,et al.  Metastatic nonseminomatous germ cell tumors of the testis , 2002, Cancer.

[10]  R. Huddart,et al.  Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse , 2000, British Journal of Cancer.

[11]  W. Wilmanns,et al.  Advances in the management of metastatic non-seminomatous germ cell tumours during the cisplatin era: a single-institution experience. , 1996, British Journal of Cancer.

[12]  G. Hutchins,et al.  Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Habbema,et al.  Perioperative mortality of elective abdominal aortic aneurysm surgery. A clinical prediction rule based on literature and individual patient data. , 1995, Archives of internal medicine.

[14]  J P Donohue,et al.  Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  T. Ulbright,et al.  Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  S. Fosså,et al.  Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  S L Hui,et al.  Validation techniques for logistic regression models. , 1991, Statistics in medicine.

[18]  C. Boetes,et al.  The importance of prognostic factors in the individual treatment of patients with disseminated germ cell tumours. , 1990, British journal of urology.

[19]  S. Fosså,et al.  Histology of tumor residuals following chemotherapy in patients with advanced nonseminomatous testicular cancer. , 1989, The Journal of urology.

[20]  D. Sleijfer,et al.  Results of adjuvant surgery in patients with stage III and IV nonseminomatous testicular tumors after cisplatin‐vinblastine‐bleomycin chemotherapy , 1988, Journal of surgical oncology.

[21]  K. Kopecky,et al.  Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer. , 1987, The Journal of urology.

[22]  F. Harrell,et al.  Evaluating the yield of medical tests. , 1982, JAMA.

[23]  D. Cox.  Two further applications of a model for binary regression , 1958 .

[24]  J. Habbema,et al.  Validation of a prediction model and its predictors for the histology of residual masses in nonseminomatous testicular cancer. , 2001, The Journal of urology.

[25]  L. Collette,et al.  Final analysis demonstrating the equivalence of 3 BEP vs 4 cycles and the 5 day schedule vs 3 days per cycle in good prognosis germ cell cancer. An EORTC / MRC Phase III Study , 2000 .

[26]  J. Habbema,et al.  Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Habbema,et al.  Predictors of residual mass histology following chemotherapy for metastatic non-seminomatous testicular cancer: a quantitative overview of 996 resections. , 1994, European journal of cancer.

[28]  S Greenland,et al.  Quantitative methods in the review of epidemiologic literature. , 1987, Epidemiologic reviews.